Regeneron Pharmaceuticals (REGN) Stock
Biotech powerhouse using genetics for eye and immune treatments. Here's the price, business snapshot, and what's worth knowing about Regeneron Pharmaceuticals in October 2026.
Regeneron Pharmaceuticals (REGN) is a US-based biotechnology company known for developing monoclonal antibody therapies and using human genetics to inform drug discovery. Its leading marketed products include EYLEA for retinal disease and Dupixent (co‑developed with Sanofi) for certain inflammatory conditions — both are material revenue drivers. The firm combines laboratory platforms (VelocImmune) and the Regeneron Genetics Center to identify and advance targets across ophthalmology, immunology, oncology and rare diseases. Investors should note Regeneron’s strengths in proprietary discovery technology and a deep pipeline, balanced by typical sector risks: R&D intensity, regulatory approval uncertainty, patent and pricing pressures, and possible revenue concentration around key drugs. With a market capitalisation near $61.4bn, the stock can be volatile around trial, approval and commercial updates. This summary is educational and not financial advice; consider your risk tolerance and consult a financial adviser to determine suitability.
Why It’s Moving
Regeneron Secures $8B Immunology Expansion with Sanofi While Highlighting New Oncology and Weight-Loss Data
- Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in future milestone payments to add four long-acting immunology antibodies to their existing Dupixent alliance, with both companies sharing development costs and profits equally.
- New Phase 2 data from the COURAGE trial showed that Regeneron's experimental drug trevogrumab prevented 70% of muscle loss associated with semaglutide treatment, addressing a key concern in the GLP-1 weight-loss market.
- Regeneron also disclosed initial study results for ubamatamab, an investigational therapy showing a high rate of durable responses in patients with advanced low-grade serous ovarian cancer, a variant with limited current treatment options.
Regeneron Secures $8B Immunology Expansion with Sanofi While Highlighting New Oncology and Weight-Loss Data
- Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in future milestone payments to add four long-acting immunology antibodies to their existing Dupixent alliance, with both companies sharing development costs and profits equally.
- New Phase 2 data from the COURAGE trial showed that Regeneron's experimental drug trevogrumab prevented 70% of muscle loss associated with semaglutide treatment, addressing a key concern in the GLP-1 weight-loss market.
- Regeneron also disclosed initial study results for ubamatamab, an investigational therapy showing a high rate of durable responses in patients with advanced low-grade serous ovarian cancer, a variant with limited current treatment options.
When is the next earnings date for REGENERON PHARMACEUTICALS INC (REGN)?
Regeneron Pharmaceuticals has a confirmed upcoming earnings report scheduled for October 30, 2026, at 8:30 AM Eastern Time. This release will cover the company's financial performance for the third quarter of fiscal year 2026. The date aligns with Regeneron’s historical pattern of reporting results approximately three months after its previous quarterly disclosure.
Why You’ll Want to Watch This Stock
Strong product drivers
EYLEA and Dupixent are significant revenue sources and shape near-term cashflow, though sales can be sensitive to competition and reimbursement changes.
Genetics-driven R&D
Regeneron’s genetics and VelocImmune platforms can accelerate target discovery and bespoke antibodies, offering scientific optionality while R&D outcomes remain uncertain.
Regulatory sensitivity
Product approvals, label changes and pricing decisions across markets materially affect valuation; investors should expect updates to move the share price.
